Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD4 CAR T cells LB1901

A preparation of autologous T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD4, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD4 CAR T cells LB1901 target and bind to CD4-expressing tumor cells, thereby inducing selective toxicity in CD4-expressing tumor cells. CD4 antigen is expressed in CD4-positive T-cell lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CAR T cells LB1901
autologous CD4-specific CAR T cells LB1901
autologous CD4-targeted chimeric antigen receptor T cells LB1901
Code name:LB 1901
LB-1901
LB1901
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search